Sanofi

By Dave Muoio and Laura Lovett 03:45 pm September 27, 2019
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
By Laura Lovett 02:54 pm September 19, 2019
Sanofi has been active in the digital space this week inking two big deals: one with tech company Abbott and the other with digital platform Happify.  The first partnership with Abbott will combine the medtech company’s FreeStyle Libre, a continuous glucose monitoring system, and the pharma giant’s insulin dosing information to create smart pens and insulin titration apps.  Sanofi is currently...

Photo Credit: MassBio

By Laura Lovett 04:13 pm September 10, 2019
Startups can have a difficult time striking a balance between the fast pace of tech culture and healthcare’s slow-and-steady validation culture. In part, the culture clash is a West Coast-East Coast divide, with tech giants congregating for the most part in California and hospitals and pharma in the Northeast, according to a panel moderated by CNBC’s Christina Farr at the MassBio Digital Health...
By Laura Lovett 01:50 pm July 3, 2019
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.  Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
By Dave Muoio 03:52 pm June 5, 2019
Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
By Dave Muoio 10:03 am May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
By MobiHealthNews 11:25 am December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.  But that wasn’t the only advance in the space as pharma...
By Dave Muoio 03:07 pm December 13, 2018
Onduo, a Verily-Sanofi joint venture focused on digitally-driven diabetes management, is looking to further protect its members from foot ulcers and limb loss. Orpyx Medical Technologies’ diabetic foot ulcer sensors for its members. Thanks to a newly announced deal struck between the companies, Orpyx Medical Technologies’ FDA-cleared SurroSense Rx system will be available to “select members” of...
By Jonah Comstock 05:44 am November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space. “These technologies have a tremendous opportunity to...
By Jonah Comstock 07:00 am October 2, 2018
Researchably, a young startup incubated at UC Berkeley, is conducting a pilot with Sanofi in China, using AI to sift through thousands of research studies and surface the most relevant ones to pharma stakeholders. “With Sanofi we’re working with a small medical communications team, and they’re in charge of every day reviewing 100 to 200 articles on Type 2 diabetes to then inform business units...